A detailed history of Two Sigma Investments, LP transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 313,993 shares of FDMT stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
313,993
Previous 105,972 196.3%
Holding current value
$1.46 Million
Previous $1.15 Million 52.66%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$5.3 - $10.41 $1.1 Million - $2.17 Million
208,021 Added 196.3%
313,993 $1.75 Million
Q3 2024

Nov 14, 2024

BUY
$10.81 - $27.22 $848,033 - $2.14 Million
78,449 Added 285.03%
105,972 $1.15 Million
Q2 2024

Aug 14, 2024

SELL
$20.93 - $30.01 $81,166 - $116,378
-3,878 Reduced 12.35%
27,523 $577,000
Q1 2024

May 15, 2024

BUY
$17.03 - $35.87 $534,759 - $1.13 Million
31,401 New
31,401 $1 Million
Q3 2023

Nov 14, 2023

SELL
$12.64 - $19.76 $1.05 Million - $1.65 Million
-83,276 Reduced 44.98%
101,863 $1.3 Million
Q2 2023

Aug 14, 2023

SELL
$15.16 - $23.26 $238,679 - $366,205
-15,744 Reduced 7.84%
185,139 $3.35 Million
Q1 2023

May 15, 2023

BUY
$15.45 - $23.19 $724,744 - $1.09 Million
46,909 Added 30.47%
200,883 $3.45 Million
Q4 2022

Feb 14, 2023

BUY
$6.85 - $25.46 $942,046 - $3.5 Million
137,525 Added 836.07%
153,974 $3.42 Million
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.48 $205,640 - $339,188
-29,546 Reduced 64.24%
16,449 $132,000
Q2 2022

Aug 15, 2022

BUY
$5.68 - $15.99 $172,075 - $484,417
30,295 Added 192.96%
45,995 $321,000
Q1 2022

May 16, 2022

SELL
$13.16 - $22.64 $725,734 - $1.25 Million
-55,147 Reduced 77.84%
15,700 $237,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $1.39 Million - $2.33 Million
70,847 New
70,847 $1.55 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $150M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.